CVS Health Corporation (NYSE:CVS) Given a $90.00 Price Target by Mizuho Analysts

CVS Health Corporation (NYSE:CVS) has been given a $90.00 target price by research analysts at Mizuho in a research note issued on Tuesday, October 24th. The brokerage presently has a “buy” rating on the pharmacy operator’s stock. Mizuho’s target price indicates a potential upside of 26.78% from the company’s previous close.

Several other research firms also recently issued reports on CVS. Royal Bank Of Canada assumed coverage on shares of CVS Health Corporation in a report on Tuesday, September 19th. They set an “outperform” rating and a $95.00 price objective on the stock. Jefferies Group LLC raised their price target on shares of CVS Health Corporation from $82.00 to $86.00 and gave the stock a “hold” rating in a research note on Friday, September 15th. Needham & Company LLC began coverage on shares of CVS Health Corporation in a research note on Tuesday, June 27th. They issued a “hold” rating on the stock. Guggenheim reissued a “buy” rating on shares of CVS Health Corporation in a research note on Monday, July 3rd. Finally, Leerink Swann set a $90.00 price target on shares of CVS Health Corporation and gave the stock a “buy” rating in a research note on Tuesday, June 27th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and fourteen have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $85.82.

Shares of CVS Health Corporation (NYSE CVS) opened at $70.99 on Tuesday. CVS Health Corporation has a twelve month low of $66.45 and a twelve month high of $84.72. The stock has a market cap of $71,912.30, a price-to-earnings ratio of 12.43, a P/E/G ratio of 1.22 and a beta of 0.86. The company has a current ratio of 1.05, a quick ratio of 0.56 and a debt-to-equity ratio of 0.67.

CVS Health Corporation (NYSE:CVS) last announced its quarterly earnings results on Monday, November 6th. The pharmacy operator reported $1.50 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.49 by $0.01. The firm had revenue of $46.18 billion for the quarter, compared to the consensus estimate of $46.17 billion. CVS Health Corporation had a net margin of 2.77% and a return on equity of 16.96%. The firm’s quarterly revenue was up 3.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.64 earnings per share. analysts anticipate that CVS Health Corporation will post 5.89 EPS for the current fiscal year.

WARNING: This piece was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The correct version of this piece can be read at https://www.dispatchtribunal.com/2017/11/12/cvs-health-corporations-cvs-buy-rating-reiterated-at-mizuho.html.

In other CVS Health Corporation news, Director Richard J. Swift sold 2,500 shares of the business’s stock in a transaction on Wednesday, August 16th. The shares were sold at an average price of $79.62, for a total value of $199,050.00. Following the transaction, the director now directly owns 3,258 shares of the company’s stock, valued at approximately $259,401.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO David M. Denton sold 237,078 shares of the company’s stock in a transaction on Monday, September 11th. The stock was sold at an average price of $79.65, for a total transaction of $18,883,262.70. Following the transaction, the chief financial officer now directly owns 141,096 shares in the company, valued at $11,238,296.40. The disclosure for this sale can be found here. Insiders sold a total of 716,625 shares of company stock worth $58,318,431 over the last three months. 0.61% of the stock is currently owned by corporate insiders.

Large investors have recently bought and sold shares of the company. Fieldpoint Private Securities LLC grew its stake in shares of CVS Health Corporation by 333.3% during the 2nd quarter. Fieldpoint Private Securities LLC now owns 1,300 shares of the pharmacy operator’s stock worth $105,000 after purchasing an additional 1,000 shares during the period. Arcadia Investment Management Corp MI grew its stake in shares of CVS Health Corporation by 119.6% during the 3rd quarter. Arcadia Investment Management Corp MI now owns 1,333 shares of the pharmacy operator’s stock worth $108,000 after purchasing an additional 726 shares during the period. MPS Loria Financial Planners LLC acquired a new position in shares of CVS Health Corporation during the 2nd quarter worth $119,000. Gemmer Asset Management LLC grew its stake in shares of CVS Health Corporation by 15.3% during the 2nd quarter. Gemmer Asset Management LLC now owns 1,509 shares of the pharmacy operator’s stock worth $121,000 after purchasing an additional 200 shares during the period. Finally, TB Alternative Assets Ltd. acquired a new position in shares of CVS Health Corporation during the 2nd quarter worth $121,000. 81.46% of the stock is currently owned by institutional investors and hedge funds.

CVS Health Corporation Company Profile

CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.

Analyst Recommendations for CVS Health Corporation (NYSE:CVS)

Receive News & Ratings for CVS Health Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply